Economic costing methodologies for drug-resistant bacterial infections in humans in low-and middle-income countries: a systematic review

Edward Masoambeta (), Charity Mkwanda, Edna Ibrahim, Kenneth Chizani, Chikondi Chapuma, Priscilla Dzanja, Edson Mwinjiwa, Raphael Chanda, Mirfin Mpundu, Luigia Scudeller, Tomislav Kostyanev, Finola Leonard, Surbhi Malhotra-Kumar, Fiammetta Bozzani, Eric Umar, Rajab Mkakosya, Chantal Morel, Chisomo Msefula and Jobiba Chinkhumba
Additional contact information
Edward Masoambeta: Kamuzu University of Health Sciences
Charity Mkwanda: Kamuzu University of Health Sciences
Edna Ibrahim: Kamuzu University of Health Sciences
Kenneth Chizani: Kamuzu University of Health Sciences
Chikondi Chapuma: Malawi Liverpool Wellcome Trust
Priscilla Dzanja: Malawi Liverpool Wellcome Trust
Edson Mwinjiwa: Kamuzu University of Health Sciences
Raphael Chanda: University of Lusaka
Mirfin Mpundu: ReAct Africa
Luigia Scudeller: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tomislav Kostyanev: Technical University of Denmark
Finola Leonard: University College Dublin
Surbhi Malhotra-Kumar: University of Antwerp
Fiammetta Bozzani: University of Bern
Eric Umar: Kamuzu University of Health Sciences
Rajab Mkakosya: Kamuzu University of Health Sciences
Chantal Morel: University of Bern
Chisomo Msefula: Kamuzu University of Health Sciences
Jobiba Chinkhumba: Kamuzu University of Health Sciences

Health Economics Review, 2025, vol. 15, issue 1, 1-15

Abstract: Abstract Background This review examined methodologies used to cost the impact of antimicrobial resistance (AMR) infections in humans from household and health system perspectives. Although extensive research has been conducted on the clinical AMR burden in low- and middle-income countries (LMICs) in terms of prevalence and other drivers of antimicrobial resistance, there is increased misuse and overuse of antibiotics which increases the risk of AMR infections compared to high-income countries. Lack of comprehensive estimates on economic costs of AMR in LMICs due to lack of standard methodologies that incorporate time biases and inference for instance, may negatively affect accuracy and robustness of results needed for reliable and actionable policies. Methods We conducted a systematic review of studies searched in PubMed and other electronic databases. Only studies from LMICs were included. Data were extracted via a modified Covidence template and a Joanna Briggs Institute (JBI) assessment tool for economic evaluations to assess the quality of the papers. Results Using PRISMA, 2542 papers were screened at the title and abstract levels, of which 148 were retrieved for full-text review. Of these, 62 articles met the inclusion criteria. The articles had a quality assessment score averaging 85%, ranging from 63 to 100%. Most studies, 13, were from China (21%), followed by 8 from South Africa (13%). Tuberculosis (TB), general bacterial, and nosocomial infection costs are the most studied, accounting for 40%, 39%, and 6%, respectively with TB common in South Africa than the rest of the countries. The majority of the papers used a microcosting approach (71%), followed by gross costing (27%), while the remainder used both. Most studies analyzed costs descriptively (61%), followed by studies using regression-based techniques (17%) and propensity score matching (5%), among others. Conclusion Overall, the use of descriptive statistics without justification, limited consideration for potential data challenges, including confounders, and short-term horizons suggest that the full AMR cost burden in humans in LMICs has not been well accounted for. Given the limited data available for these studies, the use of a combination of methodologies may help triangulate more accurate and policy-relevant estimates. While the resources to conduct such cost studies are limited, the use of modeling costs via regression techniques while adjusting for cofounding could help maximize robustness and better estimate the vast and varied burden derived directly and indirectly from AMR.

Keywords: Antimicrobial resistance; Economic costs; Costing methodologies (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-025-00644-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:15:y:2025:i:1:d:10.1186_s13561-025-00644-5

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-025-00644-5

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().